Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients: A Real-World Clinical Study.
Journal of Clinical Psychopharmacology November 21, 2025 Matteo Lupi, Alessandro Carano, Tiziano Acciavatti et al.
Purpose: Treatment-resistant depression (TRD) is a common phenomenon and a considerable clinical challenge; recently, esketamine in conjunction with an oral antidepressant (AD) has emerged as a potential treatment for TRD. Several studies have shown the efficacy of esketamine in improving depressive symptoms. This prospective study aims to explore the long-term effects of esketamine therapy on...
DOI: 10.1097/jcp.0000000000002042 (opens in new tab)
Esketamine
Humans
Antidepressive agents
Follow-up studies
+8